Abstract
It remains to be seen whether rituximab can live up to the high expectations and offer a more effective treatment for patients with AASV
MeSH terms
-
Antibodies, Antineutrophil Cytoplasmic / immunology*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
B-Lymphocytes / immunology
-
Humans
-
Immunologic Factors / therapeutic use*
-
Lymphocyte Depletion
-
Remission Induction
-
Rituximab
-
Vasculitis / drug therapy*
-
Vasculitis / immunology*
Substances
-
Antibodies, Antineutrophil Cytoplasmic
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Immunologic Factors
-
Rituximab